Stentys, after receiving CE mark approval, has expanded the indications for use of its self-apposing coronary stent. The stent can now be used in specific patient subsets such as those with tapered, aneurysmatic, ectatic (dilated) or very large vessels or those with bypass grafts.
According to a press release, the self-apposing stent is engineered to solve the dilemma of artery diameter discrepancy. Its flexible, self-expanding design takes the shape of the patient’s unique vessel anatomy and perfectly apposes to the irregular contours of a blood vessel.
The CE mark certificate of the self-apposing stent was updated on the basis of additional clinical evaluation. Contraindications such as chronic total occlusions and left main bifurcations have also been lifted. These changes allow Stentys to commercialise its self-apposing stent in new market segments that represent approximately 10% of all percutaneous coronary interventions in Europe.
“Our European customers are using the Stentys self-apposing stent for their patients with atypical vessel anatomies because this is the only available product that solves this unmet need,” said Gonzague Issenmann, chief executive officer and co-founder of Stentys
